2Wilkinson GR.Drug metabolism and variability among patients in drug response[J].N Engl J Med,2005,352 (21):2211 -2221.
3Bonello L,Camoin-Jau L,Arque S,et al.Adjusted clopido-grel loading dose according to vasodilator-stimulated phospho-protein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:a multicenter randomized prospective study[J].J Am Coll Cardiol,2008,51(14):1404-1411.
4Montalescot G,Sideris G,Meuleman C,et al.A randomized comparison of high clopidogrel loading doses in patients with non-ST segment elevation acute coronary syndromes:the AL-BION (assessment of the best loading dose of clopidogrel toblunt platelet activation,inflammation and ongoing necrosis) tri-al[J].J Am Coll Cardiol 2006,48(5):931-938.
5Patti G,Colonna G,Pasceri V,et al.Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary interven-tion:results from the ARMYDA-2 (Antiplatelet therapy for re-duction of myocardial damage during angioplasty) study[J].Cir-culation,2005,111(16):2099-2106.
6Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel non-responders among patients with stable angina pectoris sched-uled for elective coronary stent placement[J].Thromb Haemont,2003,89(5):753-787.
7Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogel for coro-nary stenting:response variability,drug resistance,and the effect of pretreatment platelet reactivity[J].Circulation,2003,107(23):2908-2913.
8Simon T,Verstuyft C,Mary-Krause M,et al.Genetic Deter-minants of Response to Clopidogrel and cardiovascular events[J].N Engl J Med,2009,360(4):363-75.
9Brandt JT,Close SL,Iturria SJ,et al.Common polymor-phisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel[J].J Thromb Haemost,2007,5(12):2429-2436.
10Society for Cardiovascular Angiography and Interventions.AC-CF / AHA Clopidogrel Clinical Alert:Approaches to the FDA "Boxed Warning":a report of the American College of Cardi-ology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association[J].Circula-tion,2010,122(5):537-557.
5Gupta A, Badyal DK, Khosla PP, et al. Effect of atorvastatin on hs- CRP in acute coronary syndrome[ J ]. Br J Clin Pharmacol,2008,66 (3) :411.
6McClung JA,Kruger AL,Ferraris A. usefulness of clopi dogrel to protect against diabetes-induced vascular damage[J].{H}American Journal of Cardiology,2010,(07):1014-1018.
7Fontana P,Gaussem P,Aiach M. P2Y12 H2 haplotype is associated with peripheral arterial disease:a case-control study[J].Circulation,2003,(24):2971-2973.
8Chang H,Yanachkov IB. Agonist and antagonist effects of diadenosine tetraphosphate,a platelet dense granule constituent,on platelet P2Y1,P2Y12 and P2X1 receptors[J].Thrombosis Research,2010,(02):159-165.
10Guidetti GF,Lova P. The G(i)-coupled P2Y12 Receptor Regulates Diacylglycerol-mediated Signaling in Human Platelets[J].Journal of Biological Chemistry,2008,(43):28795-28805.doi:10.1074/jbc.M801588200.
